StockData
Biodesix Inc logo

Biodesix Inc (BDSX) stock

BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$8.88−0.12 (-1.33%)

Close on Nov 17, 2026Market cap $93.69MP/E –Yield –

Biodesix revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Biodesix's revenue for the twelve months ending Jun 30, 2026 was $102.94M, up 34.5% year over year. For fiscal 2025 it was $88.50M, up 24.1% from the year before. The highest annual figure on record is $88.50M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$88.50M+24.1%
FY2024Dec 31, 2024$71.32M+45.3%
FY2023Dec 31, 2023$49.09M+28.5%
FY2022Dec 31, 2022$38.21M-29.9%
FY2021Dec 31, 2021$54.51M+19.6%
FY2020Dec 31, 2020$45.56M+85.6%
FY2019Dec 31, 2019$24.55M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$26.86M+34.2%
Q1 FY2026Mar 31, 2026$25.56M+42.3%
Q4 FY2025Dec 31, 2025$28.76M+40.8%
Q3 FY2025Sep 30, 2025$21.77M+19.9%
Q2 FY2025Jun 30, 2025$20.02M+11.7%
Q1 FY2025Mar 31, 2025$17.96M+21.2%
Q4 FY2024Dec 31, 2024$20.43M+39.3%
Q3 FY2024Sep 30, 2024$18.15M+34.5%
Q2 FY2024Jun 30, 2024$17.93M+51.0%
Q1 FY2024Mar 31, 2024$14.82M+63.6%
Q4 FY2023Dec 31, 2023$14.67M+52.7%
Q3 FY2023Sep 30, 2023$13.49M+21.5%
Q2 FY2023Jun 30, 2023$11.87M+8.4%
Q1 FY2023Mar 31, 2023$9.06M+38.3%
Q4 FY2022Dec 31, 2022$9.61M+33.0%
Q3 FY2022Sep 30, 2022$11.11M+70.1%
Q2 FY2022Jun 30, 2022$10.95M-7.9%
Q1 FY2022Mar 31, 2022$6.55M-77.3%
Q4 FY2021Dec 31, 2021$7.22M-73.3%
Q3 FY2021Sep 30, 2021$6.53M-29.0%
Q2 FY2021Jun 30, 2021$11.89M+180.4%
Q1 FY2021Mar 31, 2021$28.87M+466.4%
Q4 FY2020Dec 31, 2020$27.03M+226.8%
Q3 FY2020Sep 30, 2020$9.19M+133.2%
Q2 FY2020Jun 30, 2020$4.24M–
Q1 FY2020Mar 31, 2020$5.10M–
Q4 FY2019Dec 31, 2019$8.27M–
Q3 FY2019Sep 30, 2019$3.94M–

More Biodesix figures

See a number that looks wrong?